The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Importance Induction chemotherapy followed by high-dose therapy with autologous stem
cell transplant and subsequent antidisialoganglioside antibody immunotherapy is standard …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …